Back to News
investment

Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy - Slideshow

Seeking Alpha
Loading...
1 min read
1 views
0 likes
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy - Slideshow

Summarize this article with:

SA Transcripts157.37K FollowersFollow5ShareSaveCommentsThe following slide deck was published by Theravance Biopharma, Inc. in conjunction with this event. This article was written bySA Transcripts157.37K FollowersFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Read Original

Source Information

Source: Seeking Alpha